#E79242
Star Therapeutics Inc. brought on board six new investors in its oversubscribed $90 million series C round, raising the company’s total funding to more than $190 million since its founding in 2018 to advance in-house drug discovery efforts via formation of portfolio companies. Since emerging from stealth in early...
Star Therapeutics, which created two antibody-focused biotech startups with more in the works, has now reeled in a $90 million Series C. The round, disclosed Tuesday morning, brings the Bay Area biotech’s total financing to more than $190 million since emerging from Westlake Village BioPartners in early 2022. Star’s biotech startups Vega Therapeutics and Electra Therapeutics...
Investors have showered Star Therapeutics with $90 million to grow its portfolio companies and develop new antibody drugs for diseases with high unmet need. Sofinnova Investments led the oversubscribed series C round and was joined by new investors Qatar Investment Authority, Catalio Capital Management, Agent Capital, Soleus Capital and NYBC Ventures alongside all seven...
Adam Rosenthal is the CEO and founder of Star Therapeutics, [...]
Despite some big advances in recent years, rare disease remains [...]
The biotech has an unusual hub-and-spoke model that it believes [...]
Star Therapeutics aims to develop drugs for rare diseases, many [...]
© 2023 STAR Therapeutics Inc.
We look forward to connecting with you
